ASX - By Stock
|
CC9 |
Re:
Ann: Black Mountain Drilling Results
|
|
TheDerivative
|
25 |
15K |
2 |
02/02/24 |
02/02/24 |
ASX - By Stock
|
25
|
15K
|
2
|
|
ASX - By Stock
|
CC9 |
Re:
Ann: Quarterly Activities/Appendix 5B Cash Flow Report
|
|
TheDerivative
|
1 |
946 |
2 |
27/01/24 |
27/01/24 |
ASX - By Stock
|
1
|
946
|
2
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Becoming a substantial holder
|
|
TheDerivative
|
17 |
5.9K |
2 |
07/09/23 |
07/09/23 |
ASX - By Stock
|
17
|
5.9K
|
2
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Becoming a substantial holder
|
|
TheDerivative
|
17 |
5.9K |
1 |
02/09/23 |
02/09/23 |
ASX - By Stock
|
17
|
5.9K
|
1
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Change of Director's Interest Notice
|
|
TheDerivative
|
8 |
2.1K |
0 |
26/08/23 |
26/08/23 |
ASX - By Stock
|
8
|
2.1K
|
0
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Change of Director's Interest Notice
|
|
TheDerivative
|
8 |
2.1K |
2 |
25/08/23 |
25/08/23 |
ASX - By Stock
|
8
|
2.1K
|
2
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Invex to close IIH Evolve Phase III Clinical Trial
|
|
TheDerivative
|
41 |
9.6K |
2 |
22/08/23 |
22/08/23 |
ASX - By Stock
|
41
|
9.6K
|
2
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
TheDerivative
|
29 |
9.9K |
4 |
13/07/23 |
13/07/23 |
ASX - By Stock
|
29
|
9.9K
|
4
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
TheDerivative
|
29 |
9.9K |
2 |
10/07/23 |
10/07/23 |
ASX - By Stock
|
29
|
9.9K
|
2
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Director Resignations and Appointment of Non-Executive Chair
|
|
TheDerivative
|
77 |
20K |
0 |
03/07/23 |
03/07/23 |
ASX - By Stock
|
77
|
20K
|
0
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Director Resignations and Appointment of Non-Executive Chair
|
|
TheDerivative
|
77 |
20K |
0 |
03/07/23 |
03/07/23 |
ASX - By Stock
|
77
|
20K
|
0
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Director Resignations and Appointment of Non-Executive Chair
|
|
TheDerivative
|
77 |
20K |
2 |
03/07/23 |
03/07/23 |
ASX - By Stock
|
77
|
20K
|
2
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Phase III Clinical Trial Update and New IIH Market Analysis
|
|
TheDerivative
|
224 |
54K |
0 |
29/06/23 |
29/06/23 |
ASX - By Stock
|
224
|
54K
|
0
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Phase III Clinical Trial Update and New IIH Market Analysis
|
|
TheDerivative
|
224 |
54K |
1 |
28/06/23 |
28/06/23 |
ASX - By Stock
|
224
|
54K
|
1
|
|
ASX - By Stock
|
IXC |
Re:
IXC Charting Thread
|
|
TheDerivative
|
523 |
94K |
2 |
09/06/23 |
09/06/23 |
ASX - By Stock
|
523
|
94K
|
2
|
|
ASX - By Stock
|
IXC |
Re:
IXC Charting Thread
|
|
TheDerivative
|
523 |
94K |
1 |
02/06/23 |
02/06/23 |
ASX - By Stock
|
523
|
94K
|
1
|
|
ASX - By Stock
|
IXC |
Re:
IXC Charting Thread
|
|
TheDerivative
|
523 |
94K |
6 |
02/06/23 |
02/06/23 |
ASX - By Stock
|
523
|
94K
|
6
|
|
ASX - By Stock
|
IXC |
Re:
DCF Valuation Model for Invex Therapeutics
|
|
TheDerivative
|
241 |
47K |
0 |
28/03/23 |
28/03/23 |
ASX - By Stock
|
241
|
47K
|
0
|
|
ASX - By Stock
|
IXC |
Re:
Ann: German Approval for IIH EVOLVE Phase 3 Clinical Trial
|
|
TheDerivative
|
22 |
5.8K |
0 |
28/03/23 |
28/03/23 |
ASX - By Stock
|
22
|
5.8K
|
0
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Publication of Invex IIH Phase II Pressure Trial Results
|
|
TheDerivative
|
20 |
3.9K |
0 |
16/03/23 |
16/03/23 |
ASX - By Stock
|
20
|
3.9K
|
0
|
|
ASX - By Stock
|
IXC |
Re:
IXC chart
|
|
TheDerivative
|
506 |
94K |
4 |
07/02/23 |
07/02/23 |
ASX - By Stock
|
506
|
94K
|
4
|
|
ASX - By Stock
|
IXC |
Re:
IXC chart
|
|
TheDerivative
|
506 |
94K |
1 |
11/01/23 |
11/01/23 |
ASX - By Stock
|
506
|
94K
|
1
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Investor Presentation
|
|
TheDerivative
|
14 |
2.4K |
5 |
23/11/22 |
23/11/22 |
ASX - By Stock
|
14
|
2.4K
|
5
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Invex receives IND approval
|
|
TheDerivative
|
47 |
13K |
2 |
19/08/22 |
19/08/22 |
ASX - By Stock
|
47
|
13K
|
2
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Trading Halt
|
|
TheDerivative
|
39 |
7.5K |
3 |
18/08/22 |
18/08/22 |
ASX - By Stock
|
39
|
7.5K
|
3
|
|
ASX - By Stock
|
IXC |
Re:
The path to a Billion Dollar + company
|
|
TheDerivative
|
287 |
57K |
5 |
27/01/22 |
27/01/22 |
ASX - By Stock
|
287
|
57K
|
5
|
|
ASX - By Stock
|
IXC |
Re:
The path to a Billion Dollar + company
|
|
TheDerivative
|
287 |
57K |
4 |
22/01/22 |
22/01/22 |
ASX - By Stock
|
287
|
57K
|
4
|
|
ASX - By Stock
|
IXC |
Re:
The path to a Billion Dollar + company
|
|
TheDerivative
|
287 |
57K |
1 |
22/01/22 |
22/01/22 |
ASX - By Stock
|
287
|
57K
|
1
|
|
ASX - By Stock
|
IXC |
Re:
The path to a Billion Dollar + company
|
|
TheDerivative
|
287 |
57K |
1 |
20/01/22 |
20/01/22 |
ASX - By Stock
|
287
|
57K
|
1
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Top 20 Holders
|
|
TheDerivative
|
89 |
24K |
4 |
13/01/22 |
13/01/22 |
ASX - By Stock
|
89
|
24K
|
4
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Top 20 Holders
|
|
TheDerivative
|
89 |
24K |
2 |
12/01/22 |
12/01/22 |
ASX - By Stock
|
89
|
24K
|
2
|
|
ASX - By Stock
|
IXC |
Re:
IXC chart
|
|
TheDerivative
|
506 |
94K |
1 |
08/01/22 |
08/01/22 |
ASX - By Stock
|
506
|
94K
|
1
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Withdrawal of AGM Resolutions
|
|
TheDerivative
|
100 |
14K |
5 |
10/12/21 |
10/12/21 |
ASX - By Stock
|
100
|
14K
|
5
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Withdrawal of AGM Resolutions
|
|
TheDerivative
|
100 |
14K |
2 |
25/11/21 |
25/11/21 |
ASX - By Stock
|
100
|
14K
|
2
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Withdrawal of AGM Resolutions
|
|
TheDerivative
|
100 |
14K |
0 |
25/11/21 |
25/11/21 |
ASX - By Stock
|
100
|
14K
|
0
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Global Phase 3 Trial of Presendin to Launch in Q4 2021
|
|
TheDerivative
|
168 |
25K |
1 |
18/11/21 |
18/11/21 |
ASX - By Stock
|
168
|
25K
|
1
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Global Phase 3 Trial of Presendin to Launch in Q4 2021
|
|
TheDerivative
|
168 |
25K |
1 |
18/11/21 |
18/11/21 |
ASX - By Stock
|
168
|
25K
|
1
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Global Phase 3 Trial of Presendin to Launch in Q4 2021
|
|
TheDerivative
|
168 |
25K |
2 |
17/11/21 |
17/11/21 |
ASX - By Stock
|
168
|
25K
|
2
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Global Phase 3 Trial of Presendin to Launch in Q4 2021
|
|
TheDerivative
|
168 |
25K |
0 |
16/11/21 |
16/11/21 |
ASX - By Stock
|
168
|
25K
|
0
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Global Phase 3 Trial of Presendin to Launch in Q4 2021
|
|
TheDerivative
|
168 |
25K |
1 |
16/11/21 |
16/11/21 |
ASX - By Stock
|
168
|
25K
|
1
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Global Phase 3 Trial of Presendin to Launch in Q4 2021
|
|
TheDerivative
|
168 |
25K |
1 |
05/11/21 |
05/11/21 |
ASX - By Stock
|
168
|
25K
|
1
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Global Phase 3 Trial of Presendin to Launch in Q4 2021
|
|
TheDerivative
|
168 |
25K |
5 |
05/11/21 |
05/11/21 |
ASX - By Stock
|
168
|
25K
|
5
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Notice of Webinar & Investor Presentation
|
|
TheDerivative
|
32 |
4.4K |
0 |
04/11/21 |
04/11/21 |
ASX - By Stock
|
32
|
4.4K
|
0
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Global Phase 3 Trial of Presendin to Launch in Q4 2021
|
|
TheDerivative
|
168 |
25K |
1 |
04/11/21 |
04/11/21 |
ASX - By Stock
|
168
|
25K
|
1
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Global Phase 3 Trial of Presendin to Launch in Q4 2021
|
|
TheDerivative
|
168 |
25K |
1 |
04/11/21 |
04/11/21 |
ASX - By Stock
|
168
|
25K
|
1
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Notice of Annual General Meeting/Proxy Form
|
|
TheDerivative
|
172 |
18K |
1 |
29/10/21 |
29/10/21 |
ASX - By Stock
|
172
|
18K
|
1
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Notice of Annual General Meeting/Proxy Form
|
|
TheDerivative
|
172 |
18K |
1 |
29/10/21 |
29/10/21 |
ASX - By Stock
|
172
|
18K
|
1
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
TheDerivative
|
16 |
3.4K |
1 |
21/10/21 |
21/10/21 |
ASX - By Stock
|
16
|
3.4K
|
1
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Notice of Investor Call and Presentation
|
|
TheDerivative
|
154 |
21K |
4 |
01/10/21 |
01/10/21 |
ASX - By Stock
|
154
|
21K
|
4
|
|
ASX - By Stock
|
IXC |
Re:
Questions to ask Tom in relation to recent announcement dated 27.09.2021
|
|
TheDerivative
|
98 |
16K |
0 |
29/09/21 |
29/09/21 |
ASX - By Stock
|
98
|
16K
|
0
|
|